SOUTH SAN FRANCISCO, CA, USA I June 15, 2019 I Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
“We are encouraged by the data presented today demonstrating vecabrutinib’s well-tolerated safety profile and evidence of clinical activity in CLL and other B-cell malignances,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Importantly, vecabrutinib’s median steady-state trough concentrations continue to increase with dose and are approaching levels expected to provide consistent BTK inhibition and greater clinical activity. We are currently dosing patients in the 200mg cohort and momentum in the trial continues as reflected by the robust pace of enrollment we’ve seen this year. We look forward to sharing data from the additional cohorts as we complete the Phase 1b and proceed to Phase 2 later this year.”
Preliminary data reported today were available from 23 patients treated in the trial thus far. These included 19 CLL patients, two mantle cell lymphoma (MCL) patients, and two Waldenstrom Macroglobulinemia (WM) patients. Patients had received an average of 4 lines of prior therapy, and all patients had progressed on prior BTKi therapy. 61% of CLL patients enrolled had a BTK C481 mutation as of the data cutoff for the poster.
The poster builds vecabrutinib’s profile in four key areas:
- Safety: Preliminary data on treatment-emergent adverse events (TEAEs) were available for 20 patients. The most common TEAEs of any grade were anemia (40%) and neutropenia and night sweats (30% each), with 5 drug-related Grade 3 adverse events occurring in 3 patients, all in cohort 2 (50mg). In total, there were 8 serious adverse events (SAEs) in six patients, none of which were considered drug-related.
- Activity: Stable disease was seen in 4 CLL patients, 3 of whom had BTK C481S mutations. Two of these patients, both with BTK C481S mutations, showed decreases of 16% and 47% in index lesions at first assessment by CT scans. The patient with the 47% decrease was one of two evaluable post-venetoclax patients with the BTK C481S mutation. A patient with WM experienced clinical benefit with improvement in B-symptoms but no impact on immunoglobulin M. One patient in cohort 3 (100mg) continues on treatment in cycle 6 (as of the poster data cutoff, this patient was in cycle 5).
- Pharmacokinetics: The pharmacokinetic profile of vecabrutinib showed sustained exposure over the dosing interval, with median steady-state trough concentrations increasing with dose. Preliminary data showed near doubling of trough concentrations between doses of 50 mg (451 ng/mL) and 100 mg (873 ng/mL). Based on the results of the Phase 1A study in healthy subjects, trough levels of >1,000 ng/mL are expected to be required for consistent BTK inhibition and greater clinical activity. This is likely achievable with doses higher than 100 mg BID.
- Pharmacodynamics: Vecabrutinib inhibition of BTK phosphorylation was rapid and sustained in patients who had adequate baseline signal for analysis. Decreases in serum concentrations of key cytokines associated with B-cell malignancies, CCL2, CCL3, and CCL4, were observed in most evaluable patients, consistent with inhibition of BTK signaling.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new targeted therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please visit www.sunesis.com.
SOURCE: Sunesis Pharmaceuticals
Post Views: 45
SOUTH SAN FRANCISCO, CA, USA I June 15, 2019 I Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
“We are encouraged by the data presented today demonstrating vecabrutinib’s well-tolerated safety profile and evidence of clinical activity in CLL and other B-cell malignances,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Importantly, vecabrutinib’s median steady-state trough concentrations continue to increase with dose and are approaching levels expected to provide consistent BTK inhibition and greater clinical activity. We are currently dosing patients in the 200mg cohort and momentum in the trial continues as reflected by the robust pace of enrollment we’ve seen this year. We look forward to sharing data from the additional cohorts as we complete the Phase 1b and proceed to Phase 2 later this year.”
Preliminary data reported today were available from 23 patients treated in the trial thus far. These included 19 CLL patients, two mantle cell lymphoma (MCL) patients, and two Waldenstrom Macroglobulinemia (WM) patients. Patients had received an average of 4 lines of prior therapy, and all patients had progressed on prior BTKi therapy. 61% of CLL patients enrolled had a BTK C481 mutation as of the data cutoff for the poster.
The poster builds vecabrutinib’s profile in four key areas:
- Safety: Preliminary data on treatment-emergent adverse events (TEAEs) were available for 20 patients. The most common TEAEs of any grade were anemia (40%) and neutropenia and night sweats (30% each), with 5 drug-related Grade 3 adverse events occurring in 3 patients, all in cohort 2 (50mg). In total, there were 8 serious adverse events (SAEs) in six patients, none of which were considered drug-related.
- Activity: Stable disease was seen in 4 CLL patients, 3 of whom had BTK C481S mutations. Two of these patients, both with BTK C481S mutations, showed decreases of 16% and 47% in index lesions at first assessment by CT scans. The patient with the 47% decrease was one of two evaluable post-venetoclax patients with the BTK C481S mutation. A patient with WM experienced clinical benefit with improvement in B-symptoms but no impact on immunoglobulin M. One patient in cohort 3 (100mg) continues on treatment in cycle 6 (as of the poster data cutoff, this patient was in cycle 5).
- Pharmacokinetics: The pharmacokinetic profile of vecabrutinib showed sustained exposure over the dosing interval, with median steady-state trough concentrations increasing with dose. Preliminary data showed near doubling of trough concentrations between doses of 50 mg (451 ng/mL) and 100 mg (873 ng/mL). Based on the results of the Phase 1A study in healthy subjects, trough levels of >1,000 ng/mL are expected to be required for consistent BTK inhibition and greater clinical activity. This is likely achievable with doses higher than 100 mg BID.
- Pharmacodynamics: Vecabrutinib inhibition of BTK phosphorylation was rapid and sustained in patients who had adequate baseline signal for analysis. Decreases in serum concentrations of key cytokines associated with B-cell malignancies, CCL2, CCL3, and CCL4, were observed in most evaluable patients, consistent with inhibition of BTK signaling.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new targeted therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please visit www.sunesis.com.
SOURCE: Sunesis Pharmaceuticals
Post Views: 45
